



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

December 11, 2007 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:25**
 - Clinical Programs Update
 - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:25 - 7:35**
 - Buprenorphine Communication to Prescribers
 - Vivitrol® Communication to Prescribers
 - CellCept®/Myfortic® Communication to Prescribers
 - OVHA Pharmacy Bulletin re Buprenorphine PA Process, Upcoming Diabetic Testing Supply PDL Changes and Brand/Generic PDL Switches for 01/01/08
- 6. Clinical Update: Drug Reviews** **7:35 – 7:50**

(Public comment prior to Board action)

 - Symbicort® (budesonide/formoterol) Inhaler
 - Exelon® (rivastigmine) Transdermal Patch
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:50 – 8:30**

(Public comment prior to Board action)

 - Alzheimer's Medications: Cholinesterase Inhibitors/NMDA Receptor Antagonists
 - Anticoagulants
 - Anti-Infectives: Cephalosporins
 - Anti-Infectives: Genital Antivirals
 - Anti-Infectives: Topical Antibiotics
 - Gastrointestinals: Proton Pump Inhibitors
 - Growth Stimulating Agents
 - Lipotropics: Fibric Acid Derivatives
 - Lipotropics: Statins
 - Lipotropics: Miscellaneous/Combinations
 - Multiple Sclerosis Self Administered Injectables
 - Pulmonary: Beta-Adrenergic Agents

8. Drug Classes – New	8:30 – 8:30
▪ No new drug classes	
9. RetroDUR	8:30 - 8:40
▪ Mental Health Drug Use in Children 0 – 17 years	
10. New Drug Product Plan Exclusions	8:40 - 8:45
11. Updated New-to-Market Drug Monitoring Log	8:45 - 8:50
12. General Announcements	8:50 - 9:00
FDA Safety Alerts	
▪ Erythropoiesis Stimulating Agents: Aranesp [®] (darbepoetin alfa), Epogen [®] (epoetin alfa), and Procrit [®] (epoetin alfa) – hemoglobin targets	
▪ Avandia [®] (rosiglitazone maleate) Tablets – potential increased risk of myocardial ischemia	
▪ Chantix [®] (Varenicline) – suicidal thoughts, aggressive and erratic behavior	
▪ Myfortic [®] (mycophenolic acid) Delayed-Release Tablets – use in pregnancy	
13. Adjourn	9:00